Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
81 hedge funds and large institutions have $299M invested in Avadel Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 22 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 21
9% less funds holding
Funds holding: 89 → 81 (-8)
20% less capital invested
Capital invested by funds: $373M → $299M (-$74.3M)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$11.1M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$4.92M |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$3.7M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$3.04M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$40M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.7M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.37M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$5.39M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.69M |
AVDL Hedge Fund Activity: Q1 2016 in Review
81 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2016, worth a combined $299M — down 20% from $373M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AVDL and 14 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 30 added.
The largest buyer was Bank of New York Mellon, adding an estimated $11.1M. The largest seller was Janus Henderson Investors US, cutting an estimated $40M.
- 81 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2016, down from 89 in Q4 2015.
- Funds reported $299M of Avadel Pharmaceuticals stock for Q1 2016, down 20% quarter-over-quarter.
- 14 funds opened new Avadel Pharmaceuticals positions in Q1 2016 and 22 closed out, a net change of -8 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2016 was Bank of New York Mellon, an estimated $11.1M added.
- The largest Avadel Pharmaceuticals seller in Q1 2016 was Janus Henderson Investors US, an estimated $40M sold.
Based on aggregated 13F filings for Q1 2016.